Archives
Previous Opportunities
2012 Project A: Assessment of functional impact score of somatic mutations for outcome prediction in TCGA datasets (GBM, Ovarian and Colorectal)
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing Ontario Institute for Cancer Research Collaborators: Multiple collaborators Location: Ontario Institute for Cancer Research, Toronto Research Plan: Glioblastoma multiforme (GBM), Ovarian and Colorectal cancers are amongst the most malignant cancers types. In 2010, an estimated 22,000, 21,888 and 142,270 patients were diagnosed with GBM, [...]
2012 Project B: Statistical Models to Assess the Clinical Importance of Rare Genetic Variants in Cancer
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing, Ontario Institute for Cancer Research Collaborators: Dr. Ben Neel, Professor at Department of Medical Biophysics, University of Toronto, and Senior Scientist at Ontario Cancer Institute Dr. Bradly Wouters, Professor at Department of Medical Biophysics, University of Toronto, and Senior Scientist at Ontario Cancer Institute [...]
2012 Project C: Meta-Analysis of Prostate Cancer Genomic Datasets
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing, Ontario Institute for Cancer Research Collaborators: Dr. Robert Bristow, Professor at Department of Radiation Oncology, University of Toronto, Staff Radiation Oncologist at Princess Margaret Hospital/University Health Network, Senior Scientist at Ontario Cancer Institute Dr. Theo can der Kwast, Department of Laboratory Medicine and Pathology, [...]
2012 Project D: Integrated Prognostic mRNA and miRNA Signatures for Cervix Cancer Outcome
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing, Ontario Institute for Cancer Research Collaborator: Dr. Fei-Fei Liu, Professor at Department of Radiation Oncology, University of Toronto, Staff Radiation Oncologist at Princess Margaret Hospital/University Health Network, Senior Scientist at Ontario Cancer Institute Location: Ontario Institute for Cancer Research, Toronto Research Plan: Cervix cancer [...]
2012 Project E: Methodological Approaches for an Integrated Translational Pharmacogenomic Research in Esophageal Cancer: From Pre-Clinical Mouse Models to Genome Wide Association Studies and Combined Biostatistical-Bioinformatic Approaches
Supervisors: Dr. Wei Xu, Senior Biostatistician at Princess Margaret Hospital, Scientist at Ontario Cancer Institute, and Assistant Professor of Biostatistics in School of Public Health at University of Toronto Dr. Geoffrey Liu, Medical Oncologist at Princess Margaret Hospital, Pharmacogenetic Epidemiologist, Scientist at Ontario Cancer Institute, and Visiting Scientist at Harvard School of Public Health Location: [...]
2012 Project F: Genetic polymorphisms and head and neck cancer outcomesin PMH/OCI
Supervisors: Dr. Wei Xu, Senior Biostatistician at Princess Margaret Hospital, Scientist at Ontario Cancer Institute, and Assistant Professor of Biostatistics in School of Public Health at University of Toronto Dr. Geoffrey Liu, Medical Oncologist at Princess Margaret Hospital, Pharmacogenetic Epidemiologist, Scientist at Ontario Cancer Institute, and Visiting Scientist at Harvard School of Public Health Daryl [...]
2012 Project G: Multi-Marker Model in Cancer Clinical Trials
Supervisor: Dr. Keyue Ding, Senior Biostatisticians at NCIC Clinical Trials Group Location: Kingston, Ontario Research Plan: High-throughput assays have allowed researcher to discover novel biomarkers and differentially expressed genes. And various statistical issues for analyzing such data being raised, and different modelling techniques have been proposed to deal with issues. This project is to explore [...]
2011 Integrated Prognostic mRNA and miRNA Signatures for Cervix Cancer Outcome
Supervisor: Dr. Paul C. Boutros Location: Ontario Institute for Cancer Research, Toronto Cervix cancer is the second most common malignancy in women worldwide, yet to date there are no validated prognostic biomarkers in clinical use. In fact, very few such studies have yet been performed. To fill this gap, we comprehensively profiled miRNA and mRNA [...]
2011 Statistical Models to Assess the Clinical Importance of Rare Genetic Variants in Cancer
Supervisor: Dr. Paul Boutros Location: Ontario Institute for Cancer Research, Toronto Current cancer drug development typically targets oncogenes and their signalling pathways, based on the premise that tumours become “addicted” to these genes/pathways. Due to these mutations, tumours can also become unusually dependent on pathways that are not directly affected by mutation; we refer to [...]
2011 Meta-Analysis of Prostate Cancer Genomic Datasets
Supervisor: Dr. Paul Boutros Location: Ontario Institute for Cancer Research, Toronto Prostate cancer (CaP) is the most commonly diagnosed malignancy in Canadian men. In 2011, it is predicted that almost 25,000 men will be diagnosed with CaP, and more than 4,000 are expected to die from the disease. It is now the third most common [...]
